Overall medical encounters in patients with T2DM and TUD (with obesity) (Comparision between matched semaglutide vs other anti-diabetes medications cohorts)

Size/cohort	Exposure	Comparison	cases (overall risk) (Exposure)	cases (overall risk) (Comparison)	RD (95% CI)			HR (95% CI)
4,649	semaglutide	insulins	4,600 (98.9%)	4,431 (95.3%)	3.6% (3.0%, 4.3%)	 =		0.81 (0.77–0.84)
4,652	semaglutide	metformin	4,603 (98.9%)	4,528 (97.3%)	1.6% (1.1%, 2.2%)		 	1.14 (1.09–1.18)
3,514	semaglutide	DPP-4i	3,472 (98.8%)	3,399 (96.7%)	2.1% (1.4%, 2.8%)		 	1.10 (1.05–1.16)
3,617	semaglutide	SGLT2i	3,574 (98.8%)	3,516 (97.2%)	1.6% (1.0%, 2.2%)		 	1.16 (1.10–1.21)
4,056	semaglutide	SU	4,010 (98.9%)	3,886 (95.8%)	3.1% (2.4%, 3.8%)		 	1.15 (1.10–1.20)
1,609	semaglutide	TZD	1,583 (98.4%)	1,537 (95.5%)	2.9% (1.7%, 4.0%)		├ ■┤	1.16 (1.08–1.24)
4,018	semaglutide	other GLP-1RAs	3,973 (98.9%)	3,883 (96.6%)	2.2% (1.6%, 2.9%)		 	1.15 (1.10–1.20)
	0.30 0.40							